Tags

Type your tag names separated by a space and hit enter

Autosomal dominant Parkinson's disease and the route to new therapies.
Expert Rev Neurother 2007; 7(6):649-56ER

Abstract

The pathogenesis of Parkinson's disease (PD) is not understood and there are currently no accepted disease modifying, neuroprotective treatments. There are two autosomal dominant PD genes, leucine-rich repeat kinase (LRRK)2 and alpha-synuclein. LRRK2 mutations are very common in patients with PD, accounting for 40% of patients with sporadic, nonfamilial disease in some ethnic groups. Alpha-synuclein mutations are much less frequent, but the importance of alpha-synuclein has been confirmed by the demonstration of alpha-synuclein deposition as Lewy bodies in patients with PD and Lewy body dementia. Pathogenic mutations in alpha-synuclein accelerate the formation of oligomers and fibrils. Mutations in LRRK2 lead to an enhancement in LRRK2 kinase activity. The further study and understanding of the route by which alpha-synuclein and LRRK2 lead to PD, and how these processes can be therapeutically manipulated, is likely to lead to new disease-modifying treatments.

Authors+Show Affiliations

School of Medicine, Cardiff University, CF14 4XN, Wales. morrishr@cf.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17563248

Citation

Morris, Huw R.. "Autosomal Dominant Parkinson's Disease and the Route to New Therapies." Expert Review of Neurotherapeutics, vol. 7, no. 6, 2007, pp. 649-56.
Morris HR. Autosomal dominant Parkinson's disease and the route to new therapies. Expert Rev Neurother. 2007;7(6):649-56.
Morris, H. R. (2007). Autosomal dominant Parkinson's disease and the route to new therapies. Expert Review of Neurotherapeutics, 7(6), pp. 649-56.
Morris HR. Autosomal Dominant Parkinson's Disease and the Route to New Therapies. Expert Rev Neurother. 2007;7(6):649-56. PubMed PMID: 17563248.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Autosomal dominant Parkinson's disease and the route to new therapies. A1 - Morris,Huw R, PY - 2007/6/15/pubmed PY - 2007/7/4/medline PY - 2007/6/15/entrez SP - 649 EP - 56 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 7 IS - 6 N2 - The pathogenesis of Parkinson's disease (PD) is not understood and there are currently no accepted disease modifying, neuroprotective treatments. There are two autosomal dominant PD genes, leucine-rich repeat kinase (LRRK)2 and alpha-synuclein. LRRK2 mutations are very common in patients with PD, accounting for 40% of patients with sporadic, nonfamilial disease in some ethnic groups. Alpha-synuclein mutations are much less frequent, but the importance of alpha-synuclein has been confirmed by the demonstration of alpha-synuclein deposition as Lewy bodies in patients with PD and Lewy body dementia. Pathogenic mutations in alpha-synuclein accelerate the formation of oligomers and fibrils. Mutations in LRRK2 lead to an enhancement in LRRK2 kinase activity. The further study and understanding of the route by which alpha-synuclein and LRRK2 lead to PD, and how these processes can be therapeutically manipulated, is likely to lead to new disease-modifying treatments. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/17563248/Autosomal_dominant_Parkinson's_disease_and_the_route_to_new_therapies_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.7.6.649 DB - PRIME DP - Unbound Medicine ER -